

Use of NAATs for STD diagnosis of GC and CT in non-FDA-cleared anatomic specimens

By **Cybèle A. Renault, MD;**
Christopher Hall, MD, MPH;
Charlotte K. Kent, PhD;
 and **Jeffrey D. Klausner, MD, MPH**

CE CONTINUING EDUCATION

To earn CEUs, see test on page 24.

LEARNING OBJECTIVES

Upon completion of this article, the reader will be able to:

1. Describe the type of infections seen in individuals practicing high-risk sexual behaviors.
2. Compare advantages and disadvantages of NAATs.
3. Describe the protocols needed for verification studies of molecular assays.
4. Describe the current and future trends for diagnosis of gonorrhea and chlamydia infections.

The prevalence of sexually transmitted infections (STIs) is increasing in men who have sex with men (MSM).^{1,2} High-risk sexual behavior among MSM has become more common following the introduction of highly active anti-retroviral therapy (HAART)^{3,4,5,6,7} and — as a consequence — recreational drug and alcohol use.^{8,9,10} As a result, the incidence of STIs, specifically gonorrhea (GC), chlamydia (CT), and syphilis, is rising in MSM in North America as well as in Europe.^{11,12,13}

Although high-risk sexual practices are commonly recognized in MSM, the frequency of oral and anal sex is also increasing among young heterosexual adults.¹⁴ This increase in high-risk behavior could lead to an increase in the prevalence of STIs in this patient group. The rise in STIs related to high-risk sexual behavior raises concern about increases in HIV transmission, as there is evidence linking both ulcerative and non-ulcerative STIs with transmission and acquisition of HIV.¹⁵ For example, HIV-positive patients with urethral infection are known to have increased HIV-1 RNA levels in semen.¹⁶ This increase in seminal HIV viral load is highly relevant as seminal HIV-RNA levels are thought to correlate with HIV transmissibility.

It is unknown whether STIs at extra-genital sites lead to increases in HIV viral shedding similar to that seen in urethritis. It has been established, however, that gonococcal proctitis is an independent risk factor for HIV acquisition.¹⁵ This increase is presumably related to breakdown of the mucosal barrier

Continues on page 12

secondary to rectal inflammation; and, therefore, one could infer that a similar risk would be associated with other causes of proctitis, including chlamydia.

Gonorrhea and chlamydia commonly cause rectal and pharyngeal infections in MSM. Several studies report that chlamydia is found more frequently than gonorrhea in the rectum;^{17,18} in contrast, gonorrhea is more commonly isolated from the oropharynx than chlamydia.^{18,19}

There are currently 10 studies in the literature evaluating the utility of NAATs in the diagnosis of chlamydia and gonorrhea in rectal and pharyngeal specimens.

Looking at the prevalence of GC and CT infections of the rectum, Klausner, et al, retrospectively reviewed the etiology in 101 cases of clinical proctitis in MSM and found that gonorrhea and chlamydia were the most frequently recovered pathogens (30% and 19%, respectively).²⁰ Secondly, Kent, et al, used self-collected rectal swabs as a means to screen for gonococcal and chlamydial infection in MSM seeking HIV testing. Out of 174 collected rectal specimens, they found a prevalence of rectal chlamydia of 5.3%, while the prevalence of rectal gonorrhea was 2.9%.¹⁷ Similarly, Lister, et al, screened MSM for rectal infections in male-only saunas in Seattle; they detected chlamydia in 5.9% and gonorrhea in 2.2% in 507 patients screened.¹⁸ Rectal gonococcal infection is frequently seen in HIV-positive patients. Specifically, Kim, et al, studied 564 MSM and found an overall prevalence of rectal gonorrhea of 7.1%. In a subgroup analysis, prevalence of rectal gonorrhea in HIV-positive MSM was 15.2%, and was found 3.5 times more frequently in HIV-positive than HIV-negative MSM.²¹

In sexually transmitted pharyngeal infection, chlamydia is less frequently isolated than gonorrhea. For example, using

polymerase chain reaction (PCR) to test pharyngeal specimens of 521 MSM, Lister, et al, detected chlamydia in only 0.6% and gonorrhea in 2.5%.¹⁸ Prevalence of gonococcal pharyngeal infection ranges between 1% to 6% in men and women attending sexually transmitted-disease (STD) clinics. In addition, of MSM diagnosed with gonorrhea at any site, 10% to 25% have only pharyngeal infection.²²

Notably, many patients with pharyngeal and rectal gonococcal infections do not have simultaneous genital infections. Additionally, it is important to note that gonorrhea and chlamydia often cause co-infection — not only in the urethra but also in the rectum²³ and possibly the pharynx. Treatment for either organism generally requires a single dose of an antimicrobial (typically an intramuscular or oral cephalosporin for gonorrhea and an oral tetracycline or azalide for chlamydia); however, there is evidence suggesting that pharyngeal gonococcal infections are more difficult to treat and, therefore, may require a longer course of treatment.²⁴

Gonococcal and chlamydial infections are frequently asymptomatic. One study found that of 56 MSM who tested positive for either gonococcal or chlamydial urethritis, proctitis, or pharyngitis, only 23.2% reported symptoms at the relevant site.¹⁸ When symptomatic, gonococcal or chlamydial pharyngitis presents with a sore throat and can be associated with fever and enlarged submandibular lymph nodes. Gonococcal or chlamydial pharyngeal infection, however, is most frequently asymptomatic. For example, in a study in which 200 MSM in San Francisco underwent screening for pharyngeal gonorrhea, all patients who tested positive by culture or a NAAT denied symptoms.²⁵ Similarly, in a Seattle-based study, 24 of 666 men screened for gonococcal pharyngeal infection tested positive, of whom only four (16%) were symptomatic.²⁶ While proctitis may present with rectal pain, itching, rectal discharge, or bleeding, Kent, et al, found that approximately 85% of rectal gonococcal and chlamydial infections were asymptomatic.¹⁹

Table 1. Comparison of specific NAATs for the diagnosis of GC/CT infections.

	PCR (COBAS Roche Amplifier)	SDA (BD ProbeTec)	TMA (Gen-Probe Aptima)
Type of nucleic acid amplified	DNA	DNA	Ribosomal RNA (rRNA)
Nucleic-acid targets	GC: Cytosine methyl transferase gene (M: Ngo P11) or pilin gene CT: omp1 gene on cryptic plasmid	GC: pilin gene CT: omp1 gene on cryptic plasmid	GC: 16S subunit of rRNA CT: 23S subunit of rRNA
Differences in method of amplification	Primer binds to DNA gene sequence, which is subsequently amplified. Oligonucleotide probe binds to the DNA copies (amplicons), which are ultimately detected using a spectrophotometer.	Uses isothermal technique, which reduces non-specific binding of primers. Primer binds to double helix and displaces one of the strands prior to amplification. Amplified gene sequences are ultimately detected by fluorescent probes.	Only available NAAT, which amplifies RNA. Has a novel target capture step where the primer-bound nucleic acid target binds to a magnet prior to amplification, allowing substrate inhibitors to be cleansed from the sample. Amplified target is detected using two distinct light-producing labels.
Advantages	• First NAAT available	• Isothermal technique is thought to allow more efficient amplification and therefore improve sensitivity	<ul style="list-style-type: none"> • Best reproducibility profile of the available NAATs • Minimal problems with false positives due to cross-reactivity with genes from similar organisms (particularly <i>Neisseria</i> spp.) • Target capture step essentially eliminates inhibitors, thereby improving sensitivity • At least 2000 copies of r-RNA are present in each bacterium (in contrast to only a few copies of the DNA targets), leading to production of billions of copies of target RNA, thereby improving sensitivity
Disadvantages	<ul style="list-style-type: none"> • Lower specificity due to cross-reactivity with genes in non-gonococcal species (<i>N. meningitidis</i>) • Lower sensitivity as there are only a few copies of target DNA per cell • Amplification inhibitors cause false negatives 	<ul style="list-style-type: none"> • Difficulties with reproducibility and quality control • Lower specificity due to cross-reactivity with genes of related species (particularly for <i>Neisseria</i> spp.) • Amplification inhibitors cause false negatives 	

For all patients with these infections, the paucity of symptoms in extra-genital sites is problematic as asymptomatic patients frequently do not seek medical care, leading to untreated reservoirs of infection in the community. For this reason, current guidelines from the Centers for Disease Control and Prevention (CDC) recommend at least annual screening for urethral, pharyngeal, and rectal sexually transmitted diseases in MSM, regardless of symptoms.²⁷ In addition, the CDC guidelines recommend more frequent screening (three- to six-month intervals) in patients at highest risk of acquiring infection (i.e., those with multiple sex partners or those who use or whose partners use illicit drugs). Despite these recommendations, asymptomatic screening is not regularly per-

formed outside of STD clinics, largely due to physician unawareness and a perceived low prevalence of infection in asymptomatic patients. Because of the association between STDs and HIV, however, it is critical that the CDC screening recommendations be implemented.

Diagnosis of pharyngeal and rectal chlamydial and gonococcal infections

For decades, bacterial culture was the standard diagnostic modality for *Neisseria gonorrhoeae* and *Chlamydia trachomatis*. Culture of *Neisseria gonorrhoeae*, a Gram-negative diplococcus, requires plating on selective media and incubation at 36 °C in a CO₂-enriched atmosphere. This process is followed by colony identification by morphology, oxidase-positivity, and confirmation using various carbohydrate utilization or chemical tests. Other confirmation tests like direct fluorescent antibody or Gonostat are available. *Chlamydia trachomatis* is difficult to grow in culture as it is an obligate intracellular bacterium. Culture technique requires specific methods of specimen collection, transport, storage, and the use of a sensitive cell line. Importantly, because of the equipment and technique required, chlamydia culture is also relatively expensive.

Although it is the gold standard for the diagnosis of chlamydial and gonococcal infections, culture has several disadvantages. Specifically, gonococcal cultures can be falsely negative in the setting of a low bacterial load. On the other hand, false-positive gonococcal cultures may occur when cultures are taken from sites such as the pharynx, which is commonly colonized with other non-gonococcal *Neisseriae* species (e.g. *Neisseria meningitidis*). The use of the biochemical tests on suspected gonococcal colonies should obviate this disadvantage; however, their use adds additional laboratory cost and may impact turnaround time. Secondly, because chlamydia is an intracellular bacterium, its specific culture requirements are not available in all laboratories, and the culture system has modest sensitivity.

Despite the imperfections of culture, however, it remains important to maintain capacity for performance of gonorrhea culture and antimicrobial-susceptibility testing in order to monitor changing resistance patterns. This is especially true for gonorrhea, given the

increase in antibiotic resistance, particularly due to the fluoroquinolones.²⁸ In addition, bacterial culture facilitates isolate subtyping. Lastly, in the context of forensic microbiology, gonococcal and chlamydial cultures may be the method of choice for definitively establishing the diagnosis of these infections.

Because of the challenges of culture,

non-culture-based tests for gonorrhea and chlamydia have been developed. The first non-culture-based tests were enzyme immunoassays (EIA) and direct fluorescent antigen tests (DFA). Subsequently, nucleic acid hybridization probes, which detect DNA or RNA sequences, were developed. These non-culture-based tests were developed

Continues on page 14

cepheidiagnostics

Rather than say we're creating a molecular diagnostic paradigm shift, we just went ahead and shifted it.



www.cepheid.com/shift

We have made the complex simple.
We have turned days into minutes.
We have created results that empower.

We have changed the way you will look at a broad-based molecular diagnostic company.
For life.

Come feel the power. Now. 888.336.2743



Experience the power of now.™

Visit www.rsleads.com/607ml-010

Table 2. Comparison of bacterial culture and NAATs for the diagnosis of GC and CT infections.

	Culture	NAATs
Advantages	<ul style="list-style-type: none"> Nearly perfect specificity Ability to retain the isolate to perform antimicrobial susceptibility testing and isolate subtyping 	<ul style="list-style-type: none"> Do not require viable organisms for detection A single NAAT can detect GC and CT simultaneously High sensitivity, as nucleic acid can be amplified from a single organism Rapid processing (result is available often in 4 to 5 hours) Can be performed on non-invasively performed specimens (urine, self-collected vaginal swabs, self-collected rectal swabs)
Disadvantages	<ul style="list-style-type: none"> Technique is labor-intensive, difficult to standardize and expensive Long turn-around time (24 to 72 hours) Relatively poor sensitivity (particularly for CT, as it is an obligate intracellular bacterium) Decreased sensitivity if organism viability is compromised or if specimen transport, storage conditions are inadequate Decreased sensitivity in the setting of a low bacterial load 	<ul style="list-style-type: none"> Specificity may be decreased due to sample contamination if strict quality-control measures are not implemented Decreased specificity due to cross-reactivity with genes from related species (particularly for GC) Decreased sensitivity due to amplification inhibitors seen with specific NAATs (e.g., PCR, SDA) DNA-based NAATs have decreased sensitivity due to low numbers of target DNA in each bacterium Certain NAATs have difficulties with reproducibility (e.g., SDA)

for use in specimens from the urogenital tract, and with the exception of DFA, they have not been evaluated for use in the detection of gonococcal or chlamydial infection in extra-genital sites.

Nucleic acid amplification tests (NAATs) have been available since 1993 and are the newest generation of the non-culture-based tests. The NAATs detect and amplify specific bacterial DNA or RNA sequences specific for the targeted organism, and each NAAT uses a slightly different method of amplification (see Table 1). The currently available NAATs include PCR (COBAS Roche Amplicor), strand displacement amplification (SDA) (BD ProbeTec), and transcription-


mediated amplification (TMA) (Gen-Probe Aptima). The NAATs offer many advantages compared to bacterial culture (see Table 2). Of particular importance is the improved sensitivity of NAATs in comparison to culture of these two organisms. This superior sensitivity has

revolutionized the ability to diagnose gonococcal and chlamydial infections. In fact, because of their high sensitivity and specificity, NAATs have essentially replaced bacterial culture for the diagnosis of gonococcal and chlamydial urogenital infections in both men and women. Importantly, their development has improved our understanding of the epidemiology of those STIs. Additional key advantages of NAATs include use of non-invasively obtained specimens (e.g., urine), ease of provider collection of specimens for testing, and feasibility of patient self-collected specimens (e.g., vaginal swabs). Recent research demonstrated the reliability of NAATs using self-collected rectal specimens for screening in non-clinical settings.^{17,18}

STOP POPPING CAPS

and eliminate repetitive stress injury during decapping.

Pluggo Decapper™



877.251.9246 ~ lgpconsulting.com



50 TUBES PER MINUTE!
ACCOMMODATES ALL MAJOR TUBE AND CAP SIZES.

GSA CONTRACT AVAILABLE

Despite their advantages, there are several limitations of NAATs for diagnosing gonococcal and chlamydial infections. Test systems using PCR and SDA can be inhibited due to amplification inhibitors resulting in false-negative test results. Of note, inhibitors are less frequently associated with male urethral or female endocervical specimens compared with urine specimens. Examples of urine inhibitors include hemoglobin, glucose, nitrites, beta-human chorionic gonadotropin, and crystals. Laboratory methods such as dilution, heat treatment or freeze-thawing of samples have been found to reduce inhibition.²⁹ In addition, in order to identify inhibition, NAAT manufacturers have included internal controls in the test kits. Notably, one advantage of the TMA is its unique target capture step that may essentially eliminate amplification inhibition, thereby improving the sensitivity of that NAAT.

In the diagnosis of lymphogranuloma venereum (LGV), an STI caused by the *Chlamydia trachomatis* subtypes L1-L3, a limitation of commercially available NAATs for chlamydia detection is their inability to distinguish between those *Chlamydia trachomatis* subtypes (LGV (L1-L3) vs. non-LGV (A-K). From an epidemiological standpoint and because the treatment for LGV differs from treatment given for other chlamydial infections, there is a need for further advances in molecular-diagnostic testing to enable differentiation between those subtypes.

In general, NAAT processing is less labor intensive than performing culture, although care must be taken to avoid sample contamination as this can lead to false-positive test results. Of note, NAAT processing is more expensive than culture, and it is this reason that is most commonly cited by medical providers when explaining why less sensitive screening tests like culture or non-amplified tests may be preferred over NAATs.³⁰ When evaluating the cost-effectiveness of using NAATs to screen asymptomatic young women as a means to prevent pelvic inflammatory disease, however, Shafer, et al, found that the use of a NAAT to test urine specimens was not only less expensive but also increased the number of women screened when compared to the use

of cervical swab specimens collected through pelvic examination.³¹

NAATs are FDA-cleared for use with male urethral and urine as well as female endocervical and urine specimens. Most recently, TMA was FDA-cleared for use with self-collected vaginal-swab specimens.

Current research to evaluate the performance NAATs in rectal and pharyngeal specimens


There are currently 10 studies in the literature evaluating the utility of NAATs in the diagnosis of chlamydia and gonorrhea in rectal and pharyngeal specimens.^{25, 32,33,34,35,36,37,38,39,40} Verifica-

Continues on page 16

cepheidiagnostics

Transformation, metamorphosis,
alteration, reformation, revolution.

The molecular diagnostic paradigm
has shifted.



www.cepheid.com/shift

We have made the complex simple.

We have turned days into minutes.

We have created results that empower.

We have changed the way you will look at a
broad-based molecular diagnostic company.
For life.

Come feel the power. Now. 888.336.2743

Visit www.rsleads.com/607ml-011



Experience the
power of now.™

tion studies for those organisms are difficult, as frequently there is no optimal gold standard for comparison due to the lower sensitivity of culture. Therefore, those studies used an expanded reference standard that includes a positive culture result, a second confirmatory NAAT or DFA, or a confirmatory NAAT using a different primer target.

It is the difference in sensitivity which is the most striking between the NAATs and GC and CT culture (see Table 3). Generally, NAAT sensitivity is at least as good as culture, and frequently, it is superior. Specifically, for rectal gonococcal infection, TMA had the highest sensitivity, followed by SDA. PCR, which essentially has equivalent sensitivity to culture, had the lowest sensitivity of the NAATs for rectal GC. For rectal chlamydia, TMA again had the highest sensitivity, followed by PCR and, lastly, SDA. Finally, for pharyngeal gonococcal infection, TMA had the highest sensitivity, followed by SDA. PCR had the lowest sensitivity for GC detection in the pharynx. Conclusions regarding the sensitivity of NAATs for pharyngeal CT cannot be made as the prevalence across the studies was quite low (only 19 total subjects tested positive out of 694 subjects screened in the four available studies).

As with bacterial culture, the specificity of the NAATs for GC and CT detection in extra-genital sites nears 100%. Moreover, mean specificity for both organisms at both sites exceeds 95% for all NAATs, with the exception of PCR for pharyngeal gonococcal infection, which had a mean specificity 88.8%.

There are several limitations of those studies. First, the definition of infection status and the definition of true positive infection varied between studies. Secondly, the reference standards were not standardized across studies. A third limitation is

that individual studies had small sample sizes ranging from 20 to 491 total patients screened and a low frequency of infection ranging from one to 47 infected patients per study.

Overall, it appears that culture is suboptimal for the detection of gonococcal or chlamydia infection in the rectum and pharynx due to its low and variable sensitivity. Despite the limitations of available studies, NAATs appear to have great potential for use in testing non-genital specimens. Due to its consistently high sensitivity in both the pharynx and rectum, TMA appears especially promising for the detection of gonorrhea and chlamydia in the rectum and for gonorrhea in the pharynx. In contrast, PCR appears to have lower sensitivity than other NAATs for the detection of gonorrhea and chlamydia in extra-genital sites. Because they are not yet FDA-cleared for extra-genital screening, CLIA verification for NAATs at local laboratories is required prior to their use for gonorrhea and chlamydia screening in the pharynx and rectum.

CLIA verification

Most commercial and public-health laboratories utilize NAATs to test for gonorrhea and chlamydia at genital sites (e.g., cervix, urethra, vaginal swabs) as well as urine. Despite the frequency and potential public-health importance of rectal and pharyngeal gonococcal and chlamydial infections, however, limited use of NAATs for testing rectal and pharyngeal specimens persists, as commercially available NAATs have not been cleared by the FDA for these indications. Such use presently is considered off-label. Clinicians interested in non-genital gonococcal or chlamydial NAAT testing must work with their local laboratory colleagues to pursue necessary steps in the laboratory to utilize these tests for yielding clinical results. Ultimate responsibility for such verification studies rests with the local laboratory director, and with all such matters, consultation with local CLIA inspectors is essential. In addition, significant experience with nucleic amplification methods is strongly recommended prior to consideration of off-label use of these technologies.

If a laboratory is adopting an FDA-cleared test that is classified under CLIA as a high-complexity test, a study must be conducted to verify that the test performs according to the manufacturer's package insert claims. If the laboratory is adopting a test that has not been cleared by FDA or is adopting a modification of an FDA-cleared test, a more extensive study is required to establish performance specifications, because FDA-cleared package insert specifications are lacking.⁴¹

The American Society of Microbiology (www.asm.org) has published Cumitech 31, "Verification and Validation of Procedures in the Clinical Microbiology Laboratory," which provides guidance on the necessary criteria required (e.g., accuracy, precision, relevance, cost, instrumentation, and ease of performance) as new laboratory tests are verified for clinical use and established tests are validated for testing process and consistency of results.⁴² Verification is a one-time process, completed before the test or system is used for patient testing, intended to evaluate a test system to determine whether the claims stipulated by the manufacturer in the package insert as they relate to the product, the process, the results, or the interpretation can be achieved. This is contrasted with a "vali-

Table 3. Mean sensitivity and specificity of culture and NAATs for GC/CT detection in the rectum and pharynx GC rectum.

Diagnostic test	Study	Number positive tests / Total subjects screened	Combined number of positive tests	Mean sensitivity	Mean specificity
Culture	Young <i>et al.</i> Klausner <i>et al.</i>	9/227 MSM 9/205 MSM	18/432	53.2%	100%
PCR	Cook <i>et al.</i> Leslie <i>et al.</i> Klausner <i>et al.</i>	0/48 MSM 35/491 M and W 8/205 MSM	43/744	53.6%	99.1%
SDA	Klausner <i>et al.</i>	14/205 MSM	14/205	77.8%	100%
TMA	Klausner <i>et al.</i>	18/205 MSM	18/205	100%	99.5%

CT rectum

Diagnostic Test	Study	Number positive tests / Total subjects screened	Combined number of positive tests	Mean sensitivity	Mean specificity
Culture	Workowski <i>et al.</i> Cook <i>et al.</i> Klausner <i>et al.</i>	13/20 2/48 6/203	21/271	76%	100%
PCR	Workowski <i>et al.</i> Cook <i>et al.</i> Klausner <i>et al.</i> Lister <i>et al.</i>	13/20 W 2/48 MSM 11/205 MSM 47/47 MSM	73/335	91.2%	95.8%
SDA	Klausner <i>et al.</i>	13/205 MSM	13/205	76.5%	100%
TMA	Klausner <i>et al.</i>	17/205 MSM	17/205	100%	100%

GC pharynx

Diagnostic test	Study	Number positive tests / Total subjects screened	Combined number of positive tests	Mean sensitivity	Mean specificity
Culture	Stary <i>et al.</i> Page-Shafer <i>et al.</i> Young <i>et al.</i> Klausner <i>et al.</i>	2/47 M, 1/22 W 9/200 15/251 12/205	39/725	41.6%	100%
PCR	Leslie <i>et al.</i> Klausner <i>et al.</i>	7/328 M and W 12/205 MSM	19/533	65.7%	88.8%
SDA	Klausner <i>et al.</i>	15/205 MSM	15/205	75%	99.5%
TMA	Klausner <i>et al.</i>	19/205 MSM	19/205	95%	100%

Legend:
NAAT = nucleic acid amplification test, PCR = polymerase chain reaction, SDA = strand displacement amplification, TMA = transcription mediated amplification, M = men, W = women, MSM = men who have sex with men.

dation” process, aimed at documenting that a test, which has already been verified, is repeatedly yielding the expected results as the test is performed over a period of time. Validation is an integral part of the laboratory’s ongoing quality assurance program.⁴²

Since commercial NAATs are not FDA-cleared for rectal and pharyngeal specimens, individual labs may verify NAATs for non-genital sites; however, using culture as a comparison can be challenging — and if new-patient samples are used, it may require consideration by a local investigational review board. That said, the use of clinical-diagnostic specimens without patient identifiers is not human research and is exempt from human-subjects considerations as defined in the Code of Federal Regulations, Title 45, Part 46. The low sensitivity of culture in the detection of gonorrhea and chlamydia creates a problem for verification studies because the commercial NAAT may outperform the gold standard, culture. A method called latent class analysis requires using three or more conditionally independent tests to define true positives.⁴³ The performance in sensitivity and specificity of any three out of four positive or any two out of three comparators appears to be similar.⁴⁴

For instance, the San Francisco Department of Public Health Laboratory, in collaboration with colleagues at the University of California San Francisco, conducted a latent class analysis on the performance of three NAATs and culture for gonorrhea and chlamydia at non-genital sites.³⁸ In that study, the sensitivity and specificity of culture, SDA, TMA, and PCR were compared for gonorrhea and chlamydia in the pharynx and rectum. The SDA and TMA methods were found to be more sensitive than culture, while PCR was less sensitive for pharyngeal chlamydia and rectal gonorrhea. In that study, a true positive was defined by a positive culture or two or more positive NAATs.

To avoid the complexity and expense of a verification study of this scope, an alternative approach is to work with a reference laboratory that has previously verified the test by either having the reference laboratory 1) verify a suitable number of test samples, or 2) provide a panel of samples previously character-

ized by the reference lab to be tested at the lab undertaking verification. The reference lab aliquots and stores samples with a known result and the testing lab may then run the samples in its operating NAAT system. The existing NAAT system needs to have been established in accordance with CLIA regulations. The reference samples can only be used for verification of the same NAAT system that the reference lab has used unless duplicate samples are collected in separate transportation media and then tested by both methods.

The number of samples suggested for a verification of an FDA-cleared indication by the American Society of Microbiology is 20 positives and 50 negatives and by the National Committee for Clinical Laboratory Standards is 50 positives and 100 negatives.⁴² The availability of samples may be limited and, therefore, dictate the protocol; however, as the number of positives becomes less, the confidence limits of the sensitivity estimate will become broader. As such, use of fewer than 10 samples would not be recommended. Since specificity has important implications on positive predictive value, it is also important that the NAAT test ultimately will be employed in a population setting with sufficient disease prevalence to avoid excessive false-positives.

Individual labs must develop their own protocol for verification and documentation of the study must be recorded and maintained anticipating CLIA-inspector requests of the local laboratory’s verification process. The protocol design typically involves a reference panel of at least 20 positive and 20 negative specimens, obtained from a laboratory that has completed verification. The samples are run on a CLIA-approved NAAT system in the verifying laboratory. Positives and negatives, along with controls, are tested by at least two microbiologists and by a single microbiologist on different days, to demonstrate consistent results from day to day and among different operators. Target sensitivity and specificity should be equivalent to that demonstrated in the reference laboratory from which the samples are obtained.

A review of screening tests to detect gonorrhea and chlamydia, with a brief discussion of NAAT test verification,

has been published by the CDC and is available at www.cdc.gov/std/labguidelines/rr-5115.pdf.⁴¹ Further information on local laboratory verification of GC/CT NAATs may be obtained at www.std-biotraining.org/gcctnatt.

Conclusion

The significant proportion of high-risk patients found to have asymptomatic gonococcal and chlamydia infections has led to the realization that a largely unrecognized reservoir of asymptomatic infection exists, particularly among MSM. Because of the association of STIs and HIV transmission, the diagnosis and treatment of asymptomatic STIs is a crucial strategy in the prevention of HIV transmission and acquisition. Therefore, consistent with CDC guidelines, patients practicing high-risk sexual behaviors should be routinely and periodically screened for STIs, independent of symptoms.

Given the low sensitivity of gonococcal and chlamydial culture, non-culture-based testing should be expanded to facilitate the accurate and prompt diagnosis of gonorrhea and chlamydia. The development of molecular-diagnostic methods has greatly advanced the ability to diagnose STIs. Similar to their performance in urogenital infections, NAATs show great promise for the detection of chlamydia and gonorrhea using non-genital site specimens. Many experts expect that following formal evaluation of extra-genital specimen testing, use of NAATs will become the standard of care for the diagnosis of gonococcal and chlamydial infections in the pharynx and rectum. Many are urging NAAT manufacturers to request FDA clearance for the use of these tests for the testing of clinical specimens from non-genital sites to improve medical-care and -screening practices. Prior to FDA clearance, public-health officials, healthcare providers, and local laboratories should work together to perform local verification studies to facilitate the use of these molecular assays for that purpose.

There is continued excitement about advances in molecular technology and the potential uses of molecular methods to improve the ability to detect STIs. Future directions for gonorrhea and chlamydia diagnostic testing include the use of real-time PCR⁴⁵ and self-collected oral washings (e.g., mouthwash)

to detect gonococcal oropharyngeal infections.⁴⁶ Ultimately, more widespread STI screening offers multiple benefits, such as improvement in sexual health, reduced sequelae of genital and extragenital infections, and interruption of HIV transmission among those at risk for STIs. □

Cybèle A. Renault, MD, is a fellow, Infectious Diseases, Department of Medicine at Stanford University School of Medicine. **Christopher Hall, MD, MPH**, is chief, Office of Clinical Affairs, STD Branch Control Branch, California Department of Health Services, and assistant adjunct professor, Department of Medicine, at the University of California, San Francisco. **Charlotte K. Kent, PhD**, is chief, Epidemiology, Research and Surveillance, STD Prevention and Control Services at the San Francisco Department of Public Health. **Jeffrey D. Klausner, MD, MPH**, is director, STD Prevention and Control Services at the San Francisco Department of Public Health, and associate clinical professor of Medicine, Department of Medicine at the University of California, San Francisco.

Acknowledgement: Thanks to **Dr. Sheldon Morris** for his contributions to compiling technical-assistance guidance related to local laboratory verification, which informed this article, and to **Dr. Sally Liska**, director of the San Francisco Public Health Laboratory, for her tireless efforts to improve the health of the public.

References

- Centers for Disease Control and Prevention. Summary of Notifiable Diseases – United States, 2003. *MMWR Morb Mortal Wkly Rep*. 2005. Vol. 52, No. MM54;1.
- Centers for Disease Control and Prevention. Primary and secondary syphilis among men who have sex with men – New York City 2001. *MMWR Morb Mortal Wkly Rep*. 2002. Vol. 51, No. MM38;853.
- Scheer S, Chu PL, Klausner JD, et al. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. *Lancet*. 2001;357(9254):432-435.
- Dukers NH, Goudsmit J, de Wit JB, et al. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. *AIDS*. 2001;15:369-378.
- Rietmeijer CA, Patnaik JL, Judson FN, Douglas JM. Increases in gonorrhea and sexual risk behaviors among men who have sex with men: A 12-year trend analysis at the Denver Metro Health Clinic. *Sex Trans Dis*. 2003;30(7):562-567.
- Chen SY, Gibson S, Katz MH, et al. Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, CA, 1999-2001. *Am J Public Health*. 2002;92(9):1387-1388.
- Desquilbet L, Deveau C, Goujard C, et al. Increase in at-risk sexual behavior among HIV-1 infected patients followed in the French PRIMO cohort. *AIDS*. 2002;16:2329-2333.
- Bachmann LH, Grimley DM, Waitkha Y, et al. Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease prevalence among HIV-positive men receiving continuing care. *Sex Transm Dis*. 2005;32(1):20-26.
- Stueve A, O'Donnell L, Duran R, et al. Being high and taking sexual risks: Findings from a multisite survey of urban young men who have sex with men. *AIDS Educ Prev*. 2002;14:482-495.
- Woody G, Donnell D, Seage G, et al. Non-injection substance abuse correlates with risky sex among men having sex with men: data from HIVNET. *Drug Alcohol Depend*. 1999;20:495-501.
- Chen SY, Gibson S, Katz MH, et al. Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, CA, 1999-2001, USA. *Am J Public Health*. 2002;92:1387-1388.
- Fox KK, del Rio C, et al. Gonorrhea in the HIV era: a reversal in trends among men who have sex with men. *Am J Public Health*. 2001;91:959-964.
- Stolte IG, Dukers NH, de Wit JB, et al. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. *Sex Transm Infect*. 2001;77:184-186.
- Gindi RM, Ghanem KG, Erbeling E. Increases in oral and anal sexual exposure among adolescents attending STD clinics in Baltimore [abstract A3e]. Paper presented at: 2006 National STD Prevention Conference; May 8-11, 2006; Jacksonville, FL.
- Craib KJ, Meddings DR, Strathdee, SA, et al. Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. *Genitourin Med*. 1995;71(3):150-154.
- Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. *Lancet*. 1997;349:1868-1873.
- Kent CK, Dilley J, Adler B, et al. Self-collected rectal swabs – A novel method for detecting rectal chlamydia and gonorrhea among men who have sex with men seeking HIV testing services [abstract 861]. Paper presented at: Infectious Diseases Society of America 2005; October 6-9, 2005; San Francisco, CA.
- Lister NA, Smith A, Tabrizi S, et al. Screening for *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in men who have sex with men at male-only saunas. *Sex Transm Dis*. 2003;30(12):886-889.
- Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal *Chlamydia* and *Gonorrhea* detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. *Clin Inf Dis*. 2005;41(1):67-74.
- Klausner JD, Kohn R, Kent C. Etiology of clinical proctitis among men who have sex with men. *Clin Inf Dis*. 2004;38:300-302.
- Kim AA, Kent CK, Klausner JD. Risk factors for rectal gonococcal infection amidst resurgence in HIV transmission. *Sex Transm Dis*. 2003;30(11):813-817.
- Hutt DM, Judson FN. Epidemiology and treatment of oropharyngeal gonorrhea. *Ann Intern Med*. 1986;104:655-658.
- McMillan A, Manavi K, Young H. Concurrent gonococcal and chlamydial infections among men attending a sexually transmitted diseases clinic. *Int J STD AIDS*. 2005;16:357-361.
- Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. *Clin Inf Dis*. 1995;20(Suppl 1):S47-S65.
- Page-Shafer K, Graves A, Kent C et al. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhea in men who have sex with men. *Clin Inf Dis*. 2002;34:173-176.
- Lafferty WE, Hughes JP, Handsfield H, Hunter H. Sexually transmitted diseases in men who have sex with men: Acquisition of gonorrhea and nongonococcal urethritis by fellatio and implications for STD/HIV prevention. *Sex Transm Dis*. 1997;24(5):272-278.
- Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2002. *MMWR Morb Mortal Wkly Rep*. 2002;51:1-78.
- Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant *Neisseria gonorrhoeae* – Hawaii and California, 2001. *MMWR Morb Mortal Wkly Rep*. 2002;51:1041-1044.
- Verkooyen RP, Luijendijk A, Huisman WM, et al. Detection of PCR inhibitors in cervical specimens by using the Amplicor *Chlamydia trachomatis* assay. *J Clin Microbiol*. 1996;34(12):3072-3074.
- Battle TJ, Golden MR, Suchland KL, et al. Evaluation of laboratory testing methods for *Chlamydia trachomatis* infection in the era of nucleic acid amplification. *J Clin Microbiol*. 2001;39:2924-2927.
- Shafer MA, Pantell RH, Schachter J. Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? *Arch Pediatr Adolesc Med*. 1999;153:119-125.
- Stary A, Ching SF, Teodorowicz L, Lee H. Comparison of ligase chain reaction and culture for detection of *Neisseria gonorrhoeae* in genital and extragenital specimens. *J Clin Microbiol*. 1997;35(1):239-242.
- Young H, Manavi K, McMillan A. Evaluation of ligase chain reaction for the non-cultural detection of rectal and pharyngeal gonorrhoea in men who have sex with men. *Sex Transm Infect*. 2003;79:484-486.
- Lister NA, Tabrizi SN, Fairley CK, Garland S. Validation of Roche COBAS Amplicor assay for detection of *Chlamydia trachomatis* in rectal and pharyngeal specimens by an omp1 PCR assay. *J Clin Microbiol*. Jan 2004, 42(1):239-241.
- Workowski KA, Lampe MF, Wong KG, et al. Long-term eradication of *Chlamydia trachomatis* genital infection after antimicrobial therapy. Evidence against persistent infection. *JAMA*. 1993;270:2071-2075.
- Winter AJ, Gilleran G, Eastick K, Ross JDC. Comparison of a ligase chain reaction-based assay and cell culture for detection of pharyngeal carriage of *Chlamydia trachomatis*. *J Clin Microbiol*. 2000;38(9):3502-3504.
- Kessler HH, Pierer K, Stuenkel D, et al. Rapid detection of *Chlamydia trachomatis* in conjunctival, pharyngeal and urethral specimens with a new polymerase chain reaction assay. *Sex Transm Dis*. 1994;21(4):191-195.
- Klausner JD, Shayevich C, Moncada J, Liska S, Schachter J. Performance of Nucleic Acid Amplification Tests (NAATs) for *Chlamydia* and *Gonorrhea* Infections of the Oropharynx and Rectum. Paper presented at: American Society of Microbiology Annual Meeting, 2004; New Orleans.
- Cook RL, St George K, Silvestre AJ, et al. Prevalence of chlamydia and gonorrhoea among a population of men who have sex with men. *Sex Transm Infect*. 2002;78:190-193.
- Leslie LE, Azzato F, Ryan N, Fyfe J. An assessment of the Roche Amplicor *Chlamydia trachomatis/Neisseria gonorrhoeae* multiplex PCR assay in routine diagnostic use on a variety of specimens. *Commun Dis Intell*. 2003;27:373-379.
- Laboratory Guidelines for Screening To Detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* Infections — 2002. *MMWR Morb Mortal Wkly Rep*. 2002;51(RR-15);1-38.
- Elder BL, Hansen SA, Kellogg JA, Marsik FJ, Zabransky RJ. Verification and validation of procedures in the clinical microbiology laboratory [31]. In: McCurdy BW, ed. *CUMITECH: cumulative techniques and procedures in clinical microbiology*. Washington, DC: American Society for Microbiology, 1997.
- Hadgu A, Dendukuri N, Hilden J. Evaluation of nucleic acid amplification tests in the absence of a perfect gold-standard test: a review of the statistical and epidemiologic issues. *Epidemiology*. 2005;16(5):604-612.
- Martin DH, Nsuami M, Schachter J, et al. Use of multiple nucleic acid amplification tests to define the infected-patient “gold standard” in clinical trials of new diagnostic tests for *Chlamydia trachomatis* infections. *J Clin Microbiol*. 2004;42(10):4749-4758.
- Whiley DM, Buda PP, Freeman K, et al. A real-time PCR assay for the detection of *Neisseria gonorrhoeae* in genital and extragenital specimens. *Diag Microbiol Inf Dis*. 2005;52:1-5.
- Papp JR, Ahrens K, Philips C, et al. Assessment of commercial mouthwash as a novel approach to detect pharyngeal *Neisseria gonorrhoeae* infections. Paper presented at: National STD Prevention Conference; May 8-11, 2006; Jacksonville, FL.